CD29 expressed on plasma cells is activated by divalent cations and soluble CD106 contained in the bone marrow plasma: refractory activation is associated with enhanced proliferation and exit of clonal plasma cells to circulation in multiple myeloma patients E Martínez-Viñ ambres, JA García-Trujillo, E Rodríguez-Martín, LM Villar, J Coll and E Roldán Malignant plasma cells (PC) in human multiple myeloma (MM) are retained in the bone marrow (BM) microenvironment. Using HUTS21 monoclonal antibody that reacts with active CD29 integrin, we demonstrate that this active form is tightly regulated by divalent cations and soluble CD106 (sCD106) contained in the BM plasma. Moreover, we also show that in vivo expression of the active CD29 on PC was clearly diminished in a minority of MM cases (HUTS21 À patients). HUTS21 À cells were refractory to the addition of either normal allogeneic BM plasma or optimal concentrations of exogenous divalent cations and recombinant sCD106. Furthermore, a lower binding to fibronectin was detected in comparison with HUTS21 þ PC. On the other hand, although HUTS21
INTRODUCTION
Multiple myeloma (MM) is a neoplasia characterized by the accumulation and retention of malignant plasma cells (PC) within the bone marrow (BM). 1 It is true, however, that variable but very small numbers of circulating clonal PC can be detected in the majority of MM patients, although the mechanisms implicated in the release of these PC from the BM into the peripheral blood (PB) are basically unknown. 2 The influence of integrins on MM PC retention process has been widely demonstrated in the disease 3, 4 and in some experimental models. 5 The expression of other adhesion receptors on these cells in the BM have also been widely documented. 1, 6 However, it is well-known that mere expression on the cell surface is not sufficient for efficient ligand binding of integrins. They have to convert to an active state to bind their cognate ligands. 7 For CD49d/CD29 integrins, several ways of cellular activation have been described that lead to a rapid and transient increase of integrin-adhesive function. Moreover, these regulatory mechanisms do not affect cell-surface density of CD49d/CD29. 8, 9 To date, there are no clear evidences about the role of integrin activation on BM PC and its potential regulation by soluble factors contained in the BM environment. We described that an active form of the CD29 (beta1) integrin is expressed by the majority of malignant (and normal) BM PC. 10 Although this study suggested that functional state of integrin is a critical property of BM PC and may contribute to disease progression, the physiological mechanisms responsible for regulating the affinity state of CD29 on marrow PC remain still unknown. 11 On the other hand, it is well-known that integrins not only mediate cell interactions with extracellular matrix proteins, but also control tumor proliferation, survival, cell adhesion-mediated drug resistance (CAM-DR) as well as angiogenesis and metastasis. 12 In many cancer types, tumor anchorage is related with controlled proliferative activity. However, in MM, relationship between proliferative index and adhesion molecule expression is not yet clearly established. 13 We show here that the active form of CD29 on normal and malignant BM PC is basically regulated by divalent cations and soluble CD106 (sCD106) contained in the BM plasma. Interestingly, tumor cells from a minority of MM patients that express low or undetectable levels of active CD29 were refractory to these factors. Moreover, our data also show that the low-affinity state of CD29 on BM clonal PC correlates with their appearance in the PB, high PC proliferative index and diminished CAM-DR.
PATIENTS AND METHODS Patients
BM and/or PB samples from 69 MM patients, 5 PC leukemia (PCL) patients and 15 healthy subjects were studied. The diagnosis and clinical staging of these patients were made on the basis of clinical features, hematological characteristics and immunophenotyping.
14 Paired BM aspirates were obtained from 31 patients with MM before and after treatment with chemotherapy. Adhesion molecule expression was only determined in patient samples containing a sufficiently large proportion of malignant PC after therapy.
BM samples, immunophenotypic studies and patient classification After informed consent, BM was aspirated from the iliac crest and collected in heparin. Whole BM samples were stained with the following monoclonal antibody (mAb) according to the manufacturer's procedure: control IgG1-FITC, control IgG1-PE, control IgG1-PerCP, control IgG1-APC, CD38-FITC, CD29-PE (clone MAR4 and clone HUTS21), CD49d-PE, CD38-APC, CD45-PerCP, CD28-PE (BD Biosciences, San Jose, CA, USA), CD56-PE, CD19-PE, CD29-PE (4B4), CD29-FITC (K20), CD138-PE (Beckman-Coulter, Hialeah, FL, USA), CD29-PE (P5D2) (Abcam, Cambridge, UK), Kappa-FITC and Lambda-FITC (Dako, Glostrup, Denmark). Malignant (or normal) BM or PB PC were defined as CD38 with high intensity (CD38 þ þ ) and identified on a dot-plot display with side scatter vs CD38 fluorescence as the two parameters. 15 Flow-cytometric analysis was performed on a standard FACSCanto instrument (Becton Dickinson Immunocytometry Systems, San Jose, CA, USA).
Patients were divided in two groups according to their distinct HUTS21 expression on BM PC: high HUTS21 expression group (% of HUTS21 þ PC 430%, n ¼ 48; HUTS21 þ patients) and low HUTS21 expression group
Immunomagnetic isolation of PC BM PC from 9 MM patients were purified using magnetic beads coated with a mAb against the fluorochrome phycoerythrin. Briefly, anti-CD138-PE mAb was incubated with lysed and unseparated BM samples from HUTS21 þ and HUTS21 À MM patients. The positive fraction (CD138 þ cells) was obtained by repeated washes on a magnet. Purity of PC was 495% in all cases.
Autologous or allogeneic BM plasma assays and BM plasmaneutralization experiments
To obtain autologous or allogeneic BM plasma from MM and healthy subjects, aspirates were centifuged and plasmas were frozen at À70 1C until analysis. Patient BM cells (50 ml) obtained after cell sedimentation and three washing steps with phosphate-buffered saline (PBS) --BSA were mixed with 50 ml of patient autologous BM plasma or allogeneic plasma obtained from other MM or healthy specimens. Incubation was performed one hour at 37 1C. Then, cells were stained with mAbs.
In BM plasma-neutralization studies, plasma was preincubated with either specific Ab (rabbit anti-CD106, rabbit anti-SDF-1a, anti-fibronectin (FN) mAb) (R&D Systems, Minneapolis, MN, USA) or corresponding control Ab (rabbit serum at 1:400 dilution, mouse IgG2a at 10 mg/ml) for 18 h at 4 1C.
HUTS21 epitope regulation experiments with divalent cations and integrin ligands
The effect of EDTA on HUTS21 expression was established preincubating BM plasma during 30 min at room temperature with this cation chelator before plasma re-addition to cells. For experiments involving divalent cations, washed BM tumoral cells were resuspended in HEPES (4-(2-hydroxymethyl)-1-piperazine-ethanesulphonic acid) buffer to avoid precipitation of Mn 2 þ -, Mg 2 þ -or Ca 2 þ -phosphates. Then, PC were incubated in the absence (HEPES buffer) or in the presence of different cation concentrations (0.001 --10 mM) for 1 h. PC HUTS21 expression was then monitored by flow cytometry. To test the effect of ligands on HUTS21 expression (CD106 and FN), BM PC washed twice with HEPES buffer were incubated with 0.01 mM of Mn 2 þ (a concentration without any effect on integrin activation) and various concentrations of recombinant human CD106/VCAM1-Fc chimera (rCD106) (R&D Systems), purified plasma FN (Sigma, St Louis, MO, USA) or rCD54/ICAM1-Fc chimera (R&D Systems) for 1 h at 37 1C.
Adhesion assays and flow-cytometric detection of 5
Binding of PC from MM patients to human FN (Sigma Chemicals, St Louis, MO, USA) was assessed as described elsewhere. 10, 16 Incorporation of the thymidine analog, BrdU, was performed using a cell-proliferation kit (BrdU Flow kit; BD Biosciences) following the manufacturer's protocol.
Western blot
Cells were centrifuged and lysed by adding Laemmli lysis buffer. The supernatants were collected after centrifugation at 13 000 g for 20 min. Samples were subjected to SDS-polyacrylamide gel electrophoresis in 7% polyacrilamide gels and proteins were transferred to polyvinylidene fluoride membranes. The polyvinylidene fluoride membranes were blocked in 2% dried milk in PBS for 30 min. Membranes were then incubated with a biotinylated anti-CD29 polyclonal antibody (R&D Systems) diluted in 0.2% dried milk for 2 h at room temperature on a platform shaker. They were then washed three times with PBS, 0.05% Tween 20 for 10 min and incubated with streptavidin-alkaline phosphatase (Jackson Laboratories, Bar Harbor, ME, USA) diluted in 0.2% dried milk in PBS for 1 h at room temperature, washed, as described above, and stained using bromo-4-chloro-3-indolyl-phosphate and nitro blue tetrazolium.
Statistical analysis
Non-parametric methods were used to compare the expression levels of adhesion molecules and mean fluorescence intensities (MFIs) between groups (Wilcoxon rank sum tests) and to estimate correlation coefficients (Spearmen, R). Pp0.05 was considered to be statistically significant. Differences before/after chemotherapy treatment effects were calculated for each MM group with a paired Mann --Whitney test.
RESULTS
The active form of CD29 expressed by BM PC in the majority of MM patients is regulated by divalent cations and sCD106 contained in the BM plasma We first explored the expression of the active form of CD29 on BM PC. As previously reported, 10 in most MM patients (48/69), the majority of malignant PC expressed CD29 in its active state (Table 1) . These subjects were classified as HUTS21 þ MM patients. A representative example is shown in Figure 1b : the mAb HUTS21, which recognizes an activation epitope of the CD29 integrin, 17 stained an important subset of tumoral PC. Moreover, virtually all malignant BM PC from these patients expressed intermediate to high levels of the constitutive form (inactive þ active) of CD29 measured by the mAb MAR4 (Table 1 and Figure 1c ). On the basis of the high CD29 expression on PC, we further investigated which a subunits were associated with this molecule. Using flow cytometry, we found that malignant PC from HUTS21 þ patients expressed CD49d subunit (VLA-4) on their surfaces (98.8±1.3%; MFI: 22.000 ± 2.000 a.u.). Other a-integrin partners with CD29 were minimally expressed by malignant PC (data not shown). Percentages and MFIs of total CD29 and CD49d were highly correlated (R ¼ 0.90 and R ¼ 0.87, respectively; Po0.001), clearly indicating that PC use CD49d as the only partner of CD29.
On the other hand, we did not find differences between normal controls and HUTS21 þ MM patients in HUTS21 or MAR4 expression (P40.1) ( Table 1) .
We next studied the environmental factors capable to activate CD29 on malignant BM PC. To this end, we examined the effect of BM plasma on HUTS21 epitope expression. As shown in Figure 2a , þ MM patients were incubated with or without a wide range of
concentrations (0.001 --1 mM). Activated CD29 was measured by flow cytometry after staining with PE-conjugated anti-CD29 HUTS21mAb.
Active CD29 on PC is induced by cations and sCD106 E Martínez-Viñ ambres et al when autologous BM plasma was removed before HUTS21 staining, the proportion of HUTS21 þ PC was reduced significantly compared with those measured in unwashed samples. In contrast, the proportion of MAR4 þ PC did not change. The above changes were reversed after re-addition of plasma to washed samples (Figure 2b ). The effect mediated by autologous BM plasma was dose-dependent ( Figure 2c) . Moreover, as HUTS21 is a mAb that recognizes an epitope induced by divalent cations, 17 BM plasma was preincubated with the divalent cation chelator EDTA before addition to BM cells. Under these conditions, clonal PC showed a significant reduction in the levels of activated CD29 (Figure 2b ).
This observation prompted us to explore whether the divalent cations added exogenously to washed samples were capable to induce the active conformation. As shown in Figure 2d , HUTS21 epitope on BM PC was induced by Mn 2 þ in a concentrationdependent manner, from nearly 20% up to 95%, with maximal expression at 0.5 mM Mn 2 þ and half-maximal at 0.05 mM. This effect was also confirmed using 9EG7mAb, another mAb, which recognizes an epitope also induced by Mn 2 þ (data not shown As it is well-known that the active conformation of integrins also depends on extracellular ligands, 7 we next determined the contribution of sCD106 contained in the BM plasma in the induction of HUTS21 epitope on PC. To test this, BM plasma was preincubated with isotype-matched control Ab or polyclonal neutralizing anti-CD106 Ab. Incubation of BM plasma with anti-CD106 resulted in a significant decrease in HUTS21 expression on PC (Figure 3a) . Moreover, rCD106 was capable of inducing the HUTS21 epitope (in the presence of 0.01 mM Mn 2 þ , a concentration incapable of inducing HUTS21) in a concentration-dependent manner (Figure 3b) . In contrast to anti-CD106 Ab, neutralizing anti-FN Ab had no effect on the activation state of CD29 (data not shown). On the other hand, the addition of a neutralizing anti-SDF-1a polyclonal antibody to BM plasma had no significant effect on HUTS21 re-expression in our system (Figure 3a) .
Marrow PC from a minority of MM patients who expressed low or undetectable levels of HUTS21 epitope are refractory to plasma, divalent cation or sCD106 stimulation In a minority of patients with MM (21/69), malignant PC expressed low or undetectable levels of HUTS21 epitope. These subjects were classified as HUTS21 À MM patients. Although CD29 MAR4 epitope was present on virtually all malignant cells, in almost all cases PC from HUTS21
À patients expressed lower levels of MAR4 epitope than those detected in HUTS21 þ subjects (Table 1) . A representative case is shown in Figures 4a and b . This finding was corroborated using 4B4, K20, JB1A and P5D2, four additional antiCD29mAb against four different epitopes independent of the activation state of the integrin. In all cases, MFI values were decreased by 60 --70% with respect to PC from HUTS21 þ patients. Compared with malignant marrow PCs from HUTS21 þ MM patients, clonal tumoral cells that in vivo expressed low or undetectable HUTS21 levels, cannot be switched to a functional high-affinity state. Indeed, neither autologous BM plasma added to washed PC nor the addition of allogeneic BM plasma obtained from healthy subjects aspirates or from HUTS21 þ MM patients group, were capable of increasing the affinity state of the integrin (Figure 4c) .
We next analyzed separately the patients with low or undetectable HUTS21 expression. When Mn 2 þ was exogenously added to BM PC from HUTS21 À patients with low but detectable in vivo HUTS21 levels, tumor cells were only partially capable to reexpress the epitope activation. In contrast, BM PC from HUTS21 À patients with in vivo undetectable levels of HUTS21, were almost totally refractory, indicating a clear correlation between in vivo levels and response to stimulating factors (Figure 4d) . Similar results were obtained after the addition of optimal concentrations of rCD106 (data not shown).
These experiments indicate that this abnormal regulation was not mediated by a defect in the content of divalent cations or sCD106 in the BM plasma from the minor HUTS21 À MM group. To further study whether decreased active integrin levels on HUTS21 À PC was due to the expression of different forms of CD29 anchored in the membrane of these cells, PC lysates obtained from normal subjects and HUTS21 À or HUTS21 þ MM patients were subjected to SDS-polyacrylamide gel electrophoresis under reducing conditions. As shown in Figure 5 , two bands of CD29 were typically observed in westerns blots, namely a 110 kD partially glycosylated precursor and a 130 kD fully glycosylated mature form. More importantly, marrow PC from healthy individuals or from both MM groups contained identical two species of CD29 with molecular masses of 110 and 130 kDa. These results suggest that there are no differences in the CD29 integrin pool shown by PC from HUTS21 þ and HUTS21 À MM groups. Moreover, it was very interesting to find that, although the total amount of CD29 was usually diminished in HUTS21 À PC, in clear concordance with the minor intensity of MAR4 epitope detected by flow cytometry, the ratio of mature to precursor integrin isoforms was not altered.
BM PC adhesion to FN correlates with HUTS21 in vivo levels and their response to in vitro stimulation Next, we investigated whether the expression of HUTS21 activation epitope correlated with a differential adherence to FN. To this end, the binding of BM PC to FN-coated wells from HUTS21 þ and HUTS21 À patients was studied. As can be seen in Figure 6a , malignant BM PC from three HUTS21 þ patients strongly adhered to FN in the presence of Mn 2 þ , sCD106 or autologous plasma. This binding was clearly inhibited by blocking anti-CD29 (4B4) or anti-CD49d (HP2/1) mAbs, confirming the essential role of CD49d/CD29 in this process. Similar results were observed when PC were incubated with sCD106 or autologous plasma. As expected, marrow clonal PC from HUTS21 À patients with in vivo low, but detectable, levels of activated CD29 displayed a weaker in vitro adhesion to FN than those from patients with normal in vivo levels of HUTS21 epitope. These results were observed independently of the presence in the assay medium of Mn 2 þ (Figure 6a ), sCD106 or autologous (or allogeneic) plasma (data not shown).
In close agreement with these findings, BM PC from PCL patients with undetectable levels of active integrin showed a very poor binding to FN, demonstrating a clear correlation between in vivo levels, response to plasma or exogenously added factors and binding to extracellular matrix FN.
HUTS21
À MM patients have higher percentage of circulating PC than HUTS21
þ MM subjects
It is well known that careful flow-cytometry examination of PB samples reveals small numbers of PC in the blood circulation in the majority of MM patients, in coherence with the BM retention of MM cells in this disease and in contrast with other chronic B-cell tumors. We hypothesized that active CD29 status might operate in BM clonal cells to induce a significant tumor migration into PB. In fact, MM patients with normal levels of active CD29 on BM PC showed a lower PC percentage in PB (median: 0.07%; range: 0.01--0.16%; n ¼ 26) when compared with HUTS21 À subjects (median: 0.9%; range: 0.05 --3%; n ¼ 13) (Po0.01). Moreover, circulating clonal PC were detectable by flow cytometry only in a proportion of HUTS21 þ patients (16/26) . In contrast, circulating tumor cells were detectable in all HUTS21
À patients (13/13), a result which reinforces the idea that HUTS21 epitope levels influences malignant cell dissemination.
Moreover, this minor circulating-PC subset observed in both groups of patients expressed very low levels of the activated form of CD29 (8.5 ± 2%; n ¼ 29), In a similar manner, circulating (and BM) PC from patients with secondary PCL, were virtually negative for HUTS21 expression (1.7±0.8%; n ¼ 5). More importantly, when optimal Mn 2 þ concentration was added in stimulating functional assays, the expression of HUTS21 epitope in the minor PC subset detected in the majority of MM patients was almost totally divalent cation refractory. Clonal circulating PC form PCL patients were totally refractory (Figure 6b ).
À PC show higher proliferative index and lower resistance to chemotherapy in vivo compared with HUTS21
þ PC
In addition, we observed that deregulation of active CD29 implicated significant changes in PC proliferation. Using a sensitive flow-cytometry method, we detected a higher percentage of BrdU þ PC in the BM of HUTS21 À patients with regard to HUTS21 þ patients (2±0.7%, n ¼ 8 vs 1±0.3%, n ¼ 5; Po0.05). Strikingly, proliferative index increased dramatically in circulating PC, which are totally refractory to the effect of stimulating factors to activate CD29 (9.8±4.5% BrdU þ PC; n ¼ 6). This probably reflects the close association between deregulated adhesion and a loss of control of tumor-cell proliferation.
Finally, we asked whether our findings in HUTS21 expression were consistent with previous studies demonstrating that high levels of CD49d/CD29 on malignant PC contribute to the CAM-DR. To test this, we initially examined the effect of chemotherapy in HUTS21 À MM patients. In 15 matched aspirates before and after chemotherapy, the percentage of HUTS21 þ PC increased significantly with treatment (Table 2) , indicating an enrichment of HUTS21 þ tumor cells in these patients. Moreover, this increase was accompanied by a significant elevation in the MFI of MAR4 epitope. In contrast, in HUTS21 þ MM patients (n ¼ 16 matched samples), chemotherapy produced a slight, but not significant, increase in both the percentage of HUTS21 þ cells and in the MFI of MAR4 epitope.
DISCUSSION
Our present work clearly shows that the activation epitope HUTS21 on marrow PC in healthy subjects and in the majority of MM patients (HUTS21 þ patients) is tightly regulated by divalent cations and sCD106 contained in the BM plasma. In fact, densitygradient isolation methods to obtain BM cells or a single washing step of BM aspirates before HUTS21 staining cause dramatic changes in the CD29 active conformation, possibly explaining why active CD29 expression has rarely been reported in primary PC and, perhaps, in other cells. In this regard, it is very important to work with unprocessed whole BM samples to avoid the loss of HUTS21 epitope, in a similar manner to that seen with Figure 6 . (a) Differences in the adhesion to FN between PC from HUTS21 þ and HUTS21 À patients. Adhesion capacities of purified BM PC from HUTS21 þ patients (n ¼ 3), HUTS21 À patients (n ¼ 3), and PCL patients (n ¼ 3). Adhesion assays were performed either in the absence of any mAb or in the presence of mAbs (10 mg/ml) against CD29 (4B4), CD49d (HP2/1) or control mouse IgG. Assays were performed under different incubation conditions: with Mn 2 þ (0.5 mM); with sCD106 (3 mg/ml) in the presence of 0.01 mM Mn 2 þ , and with autologous BM plasma. Adhesion to FN was expressed in optical density (OD) units. Background binding to albumin was p0.05 OD and has not been substracted from the data presented. In all cases, reduction in the adhesion to FN of PC from HUTS21 À patients was statistically significant with respect to PC from HUTS21 þ patients (Po0.05). In HUTS21 þ patients, reduction in the adhesion to FN of PC mediated by blocking 4B4mAb (or HP2/1mAb) was statistically significant with respect to PC incubated with control mAb (Po0.05). (b) Lack of response to Mn 2 þ in circulating PC. The minor circulating-PC subset detected in some MM patients, and PB PC from PCL patients were incubated with different concentrations of Mn 2 þ . BM PC from a HUTS21 þ MM patient were used as positive control. HUTS21 re-expression was determined by flow cytometry. À patients before (pre) and after (post) treatment (Po0.001 and Po0.008, respectively).
Active CD29 on PC is induced by cations and sCD106 E Martínez-Viñ ambres et al phosphoproteins, which loss rapidly the phosphorylated epitope if samples are minimally manipulated. 18 Although it is well-known that divalent cations and sCD106 are outside-in signals to activate CD29, 19--21 in our knowledge, this is the first study demonstrating that activation of CD29 in primary cells is regulated by the combined effect of these factors contained in a natural microenvironment.
Our results also indicate that Mn 2 þ by itself is capable of inducing HUTS21 epitope expression on BM PC. However, it was necessarily a concentration of Mn 2 þ that was not found under physiological conditions. 22 Despite this finding, it is important to recall that bone is the main storage for Mn 2 þ in the body 23 and that it is possible that bone resorption liberates not only Ca 2 þ but also Mn 2 þ . In any case, it seems unlikely that Mn 2 þ acts as the only factor to activate CD29 in the BM microenvironment. On the contrary, it is plausible to assume that Mn 2 þ may have an important role in malignant PC adhesion to the BM environment as an adjuvant factor for sCD106.
It is known that SDF-1a and its receptor have a role in CD49d/ CD29 activation via inside-out signaling. 24 Although SDF-1a has been shown to increase MM cell adhesion to FN, 25 this chemokine had no significant effect in our system. This confirms more recent studies reporting that SDF-1a increases binding to FN without the appearance of activation epitopes on CD29 molecule. 26 These observations show that there are at least two signaling pathways that might regulate the activation of CD49d/CD29 on BM PC. Although it is possible that both classes of signals are required to generate sufficient numbers of activated integrins, their relative contribution to the total active structure is uncertain. In our opinion, however, signals that induce rapid and transient effects on cells, 27 as in the case of chemokines, are not probably the most efficient agents to retain PC in BM during long periods of time. On the contrary, signals that mediate permanent effects on integrin activation are, a priori, excellent candidates for regulating PC retention. Divalent cations and sCD106 could fulfil these requirements as they bind directly to the integrin and also because it is likely that their concentrations in the BM environment are more constant and stable in comparison with SDF-1a.
Importantly, we found that a minority of MM patients expressed low or undetectable HUTS21 epitope levels (HUTS21 À patients). Moreover, we demonstrate in vitro that loss of in vivo active CD29 correlates with a significant reduction in integrin activation in response to either sCD106 or Mn 2 þ . The lack of response was not owing to structural alterations in CD29 on HUTS21 À PC, because immunoblot analysis demonstrated two bands, corresponding to mature and precursor species of this molecule, of the expected molecular sizes. This is important as glycosylation regulates integrin function and it is well documented that altered glycosylation may induce functional changes in adhesion proteins and in this way decrease the binding capacity of integrins to FN, possibly by holding the conformation in the low-affinity state to the ligand. 28 Our data showing that CD29 expressed by malignant PC from both groups of MM patients showed identical electrophoretic mobility in SDS-polyacrylamide gels, strongly suggest that the glycosylation patterns on both mature and precursor CD29 isoforms are indistinguishable in HUTS21 þ and HUTS21 À cells. Moreover, similar relative expression of both integrin isoforms was found in healthy subjects and patients, suggesting similar maturation process in endoplasmic reticulum and Golgi complex. This is in contrast with other tumors in which glycosylation profile of CD29 changes with progression. 29, 30 Another possible explanation for the lack of response to sCD106 and cations could be the existence of point mutations affecting the CD29 domain recognized by the HUTS21mAb, rather than gross structural alterations of the CD29 gene. If this was the case, the resulting protein could not be distinguished by western blot analysis. In this line, it has been described a mutation in the I-like domain of CD29 gene in human epithelial cell carcinoma that results in constitutive CD29 activation and sustained spreading on FN. 31 To our knowledge, this is the only example in human primary cells in which a mutation in the CD29 gene affects the function of this integrin. In fact, cells from patients with leukocyte adhesion deficiency exhibit an activation defect in this integrin, which is not associated with mutations in the CD29 gene. 32 Moreover, the only polymorphism described so far within the encoding region of this gene generates a functional protein. 33 Therefore, the absence of mutations in the vast majority of pathological or tumoral cell models investigated to date probably indicates that mutations in this gene are not important contributors to the phenotypical variants in CD29 protein. An alternative explanation could be that this adhesion defect in PC from HUTS21 À MM patients is not caused by changes in the CD29 itself, but by an alteration in one or more proteins that interact with CD29 integrin. 7 By contrast, the observation that HUTS21
À PC express the same species of CD29 as that of HUTS21 þ PC, together with the fact that four different mAb anti-CD29, recognizing four different domains of the molecule, detect similar decreased amounts of CD29, clearly suggests that HUTS21
À PC synthesize a minor quantity of this adhesion molecule. The existence of a correlation between functional state and expression levels of CD29 integrin has not been clearly demonstrated yet. However, it cannot be excluded that changes in the density of CD29 can be accompanied by concurrent changes in its function. 34 On the other hand, the affinity of integrins, such as CD61 or CD11a, not only is the result of conformational changes but also may vary depending on the cell type in which they are expressed. 35, 36 These findings indicate that unknown cell type-specific factors may control the functional activities of integrins. 37 Perhaps this is also the reason explaining why FN is capable of activating CD29 on circulating T cells, 38 whereas it has no effect on BM PC. Our results also show an impaired in vitro adhesion to FN, which is consistent with the fact that higher numbers of circulating PC are detected in vivo in HUTS21 À patients. Detection of malignant PC in PB by flow cytometry is a common finding in MM patients, 2 although no correlation with a specific integrin molecule profile has been established. 6, 39 In contrast, we described here that CD29 in a low-affinity state enhances the egress of MM cells from BM into the circulation, establishing an association between the absence of activated CD29 and a metastatic phenotype in MM.
Moreover, HUTS21 À PC showed a higher proliferative index than HUTS21 þ cells. Therefore, deactivation of CD29 not only is related with decreased adhesion but also probably associates with enhanced proliferation. As integrin also regulates proliferation in other cell models 40 and is a central and independent prognostic factor in MM, 41, 42 one of the important questions that will require further investigation is how CD29 integrin deregulation modulates PC proliferation.
Finally, we show here that, in HUTS21 À MM patients, the minor HUTS21 þ PC subset contained in BM aspirates before treatment is selectively enriched after chemotherapy administration. Therefore, these results also suggest that HUTS21 þ cells have a greater CAM-DR potential in vivo than HUTS21 À MM cells. This result is in line with previous studies suggesting that the high expression of CD29/CD49d on tumor PC is a response predictor to chemotherapy. 43 --45 However, it is important to note that when HUTS21 À patients relapse, the major PC subset present in the BM aspirate is, again, HUTS21 À (data not shown). This fact is probably owing to the highest proliferative index in this PC subset, and may provide guidance in the design of strategies in the treatment of MM. In this regard, our results suggest that the combination of agents that decrease adhesion (that is, bortezomib) with one that blocks the cell cycle (that is, vincristine) may be particularly effective for this disease.
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